PhRMA finds more than 400 biotech products in pipeline

August 21, 2006

A new PhRMA report finds that more than 400 biotechnology drugs are currently in clinical trials or awaiting approval from the FDA. Of the total, 210 are to treat cancer, 50 are for fighting infectious diseases, 44 for autoimmune disorders, and 22 for both HIV infection and cardiovascular disease.

PhRMA finds more than 400 biotech products in pipeline

A new PhRMA report finds that more than 400 biotechnology drugs are currently in clinical trials or awaiting approval from the FDA. Of the total, 210 are to treat cancer, 50 are for fighting infectious diseases, 44 for autoimmune disorders, and 22 for both HIV infection and cardiovascular disease. The product types in development include therapeutic vaccines, monoclonal antibodies, antisense products, and gene therapy. PhRMA's report can be accessed on-line at http://www.phrma.org/files/Biotech%202006.pdf.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.